Ken Fisher Gilead Sciences, Inc. Transaction History

Fisher Asset Management, LLC

$213 Billion
Q1 2024

A detailed history of Ken Fisher (Fisher Asset Management, LLC) transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Fisher Asset Management, LLC holds 13,094 shares of GILD stock, worth $841,551. This represents 0.0% of its overall portfolio holdings.

Number of Shares

13,094

Previous 12,306 6.4%

Holding current value

$841,551

Previous $996,000 3.71%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	BUY	$71.58 - $87.29 $56,405 - $68,784	788 Added 6.4%	13,094 $959,000
Q4 2023 Mar 05, 2024	SELL	$73.27 - $83.09 $44,474 - $50,435	-607 Reduced 4.7%	12,306 $996,000
Q4 2023 Feb 06, 2024	SELL	$73.27 - $83.09 $56,344 - $63,896	-769 Reduced 5.62%	12,913 $1.05 Million
Q3 2023 Nov 13, 2023	SELL	$73.94 - $80.67 $1,922 - $2,097	-26 Reduced 0.19%	13,682 $1.03 Million
Q2 2023 Dec 12, 2023	BUY	$76.01 - $86.7 $1,976 - $2,254	26 Added 0.19%	13,708 $1.06 Million

Q2 2023 Aug 08, 2023	BUY	$76.01 - $86.7 $165,777 - $189,092	2,181 Added 18.92%	13,708 $1.06 Million
Q1 2023 Dec 12, 2023	SELL	$77.31 - $88.08 $160,727 - $183,118	-2,079 Reduced 15.2%	11,603 $962,000
Q1 2023 May 01, 2023	SELL	$77.31 - $88.08 $104,909 - $119,524	-1,357 Reduced 10.53%	11,527 $956,000
Q4 2022 Feb 03, 2023	SELL	$62.32 - $89.47 $47,425 - $68,086	-761 Reduced 5.58%	12,884 $1.11 Million
Q3 2022 Nov 08, 2022	BUY	$59.54 - $68.01 $111,935 - $127,858	1,880 Added 15.98%	13,645 $842,000
Q2 2022 Aug 09, 2022	BUY	$57.72 - $65.01 $311,514 - $350,858	5,397 Added 84.75%	11,765 $727,000
Q1 2022 May 05, 2022	SELL	$57.92 - $72.58 $109,121 - $136,740	-1,884 Reduced 22.83%	6,368 $379,000
Q4 2021 Feb 02, 2022	BUY	$64.88 - $73.64 $22,059 - $25,037	340 Added 4.3%	8,252 $599,000
Q3 2021 Oct 26, 2021	SELL	$67.69 - $73.03 $73,849 - $79,675	-1,091 Reduced 12.12%	7,912 $553,000
Q2 2021 Jul 27, 2021	SELL	$63.47 - $69.35 $16,502 - $18,031	-260 Reduced 2.81%	9,003 $620,000
Q1 2021 Apr 27, 2021	SELL	$60.0 - $68.46 $6,060 - $6,914	-101 Reduced 1.08%	9,263 $599,000
Q4 2020 Jan 29, 2021	BUY	$56.65 - $64.55 $151,085 - $172,154	2,667 Added 39.82%	9,364 $546,000
Q3 2020 Nov 10, 2020	BUY	$62.1 - $78.08 $199,527 - $250,871	3,213 Added 92.22%	6,697 $423,000
Q2 2020 Aug 07, 2020	SELL	$72.34 - $84.0 $100,552 - $116,760	-1,390 Reduced 28.52%	3,484 $268,000
Q1 2020 Apr 28, 2020	SELL	$62.63 - $80.22 $31.4 Million - $40.2 Million	-500,913 Reduced 99.04%	4,874 $364,000
Q4 2019 Feb 12, 2020	SELL	$61.62 - $67.78 $9.03 Million - $9.93 Million	-146,467 Reduced 22.46%	505,787 $32.9 Million
Q3 2019 Oct 29, 2019	BUY	$62.51 - $69.0 $1.83 Million - $2.02 Million	29,203 Added 4.69%	652,254 $41.3 Million
Q2 2019 Jul 30, 2019	BUY	$61.87 - $69.38 $448,557 - $503,004	7,250 Added 1.18%	623,051 $42.1 Million
Q1 2019 Apr 22, 2019	BUY	$62.53 - $70.05 $1.13 Million - $1.26 Million	18,041 Added 3.02%	615,801 $40 Million
Q4 2018 Jan 25, 2019	BUY	$60.54 - $79.0 $2.31 Million - $3.02 Million	38,205 Added 6.83%	597,760 $37.4 Million
Q3 2018 Oct 24, 2018	SELL	$71.28 - $78.92 $926 - $1,025	-13 Reduced -0.0%	559,555 $43.2 Million
Q2 2018 Jul 09, 2018	BUY	$64.88 - $75.68 $2.02 Million - $2.35 Million	31,109 Added 5.89%	559,568 $39.6 Million
Q1 2018 May 11, 2018	SELL	$72.84 - $88.8 $27.9 Million - $34.1 Million	-383,481 Reduced 42.05%	528,459 $39.8 Million
Q1 2018 Apr 19, 2018	BUY	$72.84 - $88.8 $34.2 Million - $41.7 Million	469,166 Added 105.96%	911,940 $68.8 Million
Q4 2017 Jan 24, 2018	SELL	$71.15 - $83.52 $1.89 Million - $2.22 Million	-26,626 Reduced 5.67%	442,774 $31.7 Million
Q3 2017 Oct 17, 2017	BUY	$72.11 - $85.47 $33.8 Million - $40.1 Million	469,400	469,400 $38 Million

Others Institutions Holding GILD

# of Institutions

1,884

Shares Held

Call Options Held

8.71M

Put Options Held

8.02M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $80.6B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track Ken Fisher's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fisher Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fisher Asset Management, LLC and Ken Fisher with notifications on news.

Account